The Global RESCON Summit Europe 2026 will take place in Porto, Portugal, on November 10–11, 2026, bringing together global leaders in inhalation science, respiratory drug delivery, connected devices, and regulatory strategy. The summit examines the full respiratory innovation ecosystem — from advanced formulation and particle engineering to smart connected inhalers, sustainable device design, and scalable manufacturing.
The 2026 agenda will cover next-generation inhaled therapeutics including biologics, LNPs, and mRNA platforms, alongside DPI, pMDI, nebulized, and wearable delivery systems. Sessions will address human factors integration, quality risk management, translational in vitro models, and imaging tools supporting robust product development.
Regulatory authorities and industry experts will explore evolving global pathways for combination products, OIP generics, and real-world evidence integration, while strategic discussions will examine commercialization and capital allocation trends shaping respiratory innovation.
RESCON Europe 2026 offers a high-level forum for scientific exchange, regulatory insight, and meaningful industry collaboration.
Over 20+ Sessions , several networking opportunities in a special venue chosen by our team makes this event unique and unforgettable
1. Next-Generation Inhaled Therapeutics
Small molecules, biologics, LNPs, mRNA, and systemic delivery strategies redefining respiratory and pulmonary medicine.
2. Platform Engineering & Device Performance
DPI, pMDI, nebulized, and wearable systems optimized for consistent deposition and patient variability.
3. Smart Connected Inhalers & Digital Ecosystems
Data-driven adherence, remote monitoring, and digital therapeutics transforming value-based respiratory care.
4. Advanced Particle Engineering & Formulation Science
Micronization, morphology control, excipient strategy, and spray drying for stable, high-performance inhaled APIs.
5. Sustainability & Eco-Design
Low-GWP propellants, recyclable materials, and lifecycle strategies driving greener respiratory solutions.
6. Human Factors & Patient-Centric Design
Usability validation, behavioral design, and regulatory-ready human factors integration.
7. Translational Models & Analytical Excellence
Lung-on-chip systems, imaging tools, extractables/leachables testing, and performance analytics ensuring safety and robustness.
8. Regulatory Strategy & Global Convergence
EMA, FDA, and MHRA expectations for combination products, OIP generics, and fast-track approval pathways.
9. Real-World Evidence & Lifecycle Management
Leveraging connected devices and epidemiological data to strengthen regulatory and post-market strategy.
10. Capital Allocation & Commercial Pathways
Investor and pharma insights on what technologies scale, attract funding, or face market rejection.
Members of board, C-level, Senior Vice Presidents, Vice Presidents, Directors and Heads of departments of:
November 10-11, 2026 @Porto, Portugal (EUROPE)
© 2017 Copyright All Rights Reserved | Powered by EPM Group